Scholarlink

Background <p>Advances in understanding the molecular landscape of gastroesophageal junction (GEJ) adenocarcinoma underscore the need for biomarker-driven treatment approaches.</p> Materials and Methods <p>The Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group has developed practice guidelines for the biomarker-based management of nonmetastatic GEJ adenocarcinoma, with specific integration of microsatellite instability (MSI) status.</p> Results <p>Although multimodal therapy has improved outcomes, treatment strategies for GEJ adenocarcinoma remain largely stage-based rather than biomarker-directed. With emerging evidence supporting the prognostic and predictive roles of MSI-high (MSI-H), human epidermal growth factor receptor 2 (HER2), and other novel targets, there is an urgent need for clear guidance on how to incorporate biomarkers into the management of resectable disease.</p> Conclusions <p>These guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Hideo Takahashi,
  • Ahmed Dehal,
  • Haejin In,
  • Steve Kwon,
  • Mariam Eskander,
  • Roberto J. Vidri,
  • Brett L. Ecker,
  • Erin Ward,
  • Prejesh Philips,
  • Ioannis T. Konstantinidis,
  • Nasreen Vohra,
  • Brian Kaplan,
  • Geoffrey Nunns,
  • Jeremy Davis,
  • Travis E. Grotz,
  • Richelle Williams,
  • Moshim Kukar

摘要

Background

Advances in understanding the molecular landscape of gastroesophageal junction (GEJ) adenocarcinoma underscore the need for biomarker-driven treatment approaches.

Materials and Methods

The Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group has developed practice guidelines for the biomarker-based management of nonmetastatic GEJ adenocarcinoma, with specific integration of microsatellite instability (MSI) status.

Results

Although multimodal therapy has improved outcomes, treatment strategies for GEJ adenocarcinoma remain largely stage-based rather than biomarker-directed. With emerging evidence supporting the prognostic and predictive roles of MSI-high (MSI-H), human epidermal growth factor receptor 2 (HER2), and other novel targets, there is an urgent need for clear guidance on how to incorporate biomarkers into the management of resectable disease.

Conclusions

These guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.